Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells

BACKGROUND: The mammalian target of rapamycin (mTOR) is frequently activated in colon cancers due to mutations in the phosphatidylinositol 3-kinase (PI3K) pathway. Targeting mTOR with allosteric inhibitors of mTOR such as rapamycin reduces colon cancer progression in several experimental models. Rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Blaser, Benjamin, Waselle, Laurent, Dormond-Meuwly, Anne, Dufour, Marc, Roulin, Didier, Demartines, Nicolas, Dormond, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314574/
https://www.ncbi.nlm.nih.gov/pubmed/22401294
http://dx.doi.org/10.1186/1471-2407-12-86

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314574/
https://www.ncbi.nlm.nih.gov/pubmed/22401294
http://dx.doi.org/10.1186/1471-2407-12-86

Ejemplares similares